Actuate Therapeutics Inc
ACTU
NASDAQ
Biotechnology
$1.01
USD
+0.03 (+3.58%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $24.40M
Volume 109.6K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-21.54M
TTM
— YoY
Operating Cash Flow
$-19.60M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.1 | 3.2 | 3.3 | 2.6 | 3.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 6.4 | 6.0 | 5.5 | 4.7 | 5.7 |
Operating Income | -6.4 | -6.0 | -5.5 | -4.7 | -5.7 |
EBITDA | -6.4 | -6.0 | -5.5 | -4.7 | -5.7 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 |
Income Before Income Taxes | -6.3 | -5.9 | -5.4 | -4.6 | -5.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -6.3 | -5.9 | -5.4 | -4.6 | -5.6 |
Consolidated Net Income / Loss | -6.3 | -5.9 | -5.4 | -4.6 | -5.6 |
Net Income Attributable to Common Shareholders | -6.3 | -5.9 | -5.4 | -4.6 | -5.6 |
Basic EPS | -$0.32 | -$0.30 | -$0.25 | -$0.19 | -$0.24 |
Diluted EPS | -$0.32 | -$0.30 | -$0.25 | -$0.19 | -$0.24 |
Basic Shares Outstanding | 19.5M | 19.6M | 21.4M | 23.5M | 23.5M |
Diluted Shares Outstanding | 19.5M | 19.6M | 21.4M | 23.5M | 23.5M |